Development of vaccines for high-risk ductal carcinoma in situ of the breast.
Certain ductal carcinoma in situ (DCIS) lesions overexpress the HER-2/neu receptor at this early stage of breast cancer development. Recently, we showed that a HER-2-targeted dendritic cell vaccine could be used to eliminate HER-2-overexpressing cells in patients that harbor these high-risk DCIS lesions. Our findings suggest that vaccinating such patients might diminish the risk of recurrence, protect against the development of invasive breast cancer, and minimize morbidity associated with current treatments. We discuss several implications of this work for developing effective cancer vaccines.
Czerniecki
Brian J
BJ
Department of Surgery, Harrison Department of Research, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. brian.czerniecki@uphs.upenn.edu
Roses
Robert E
RE
Koski
Gary K
GK
D001943:Breast Neoplasms / Q000628:therapy*; D019496:Cancer Vaccines; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000628:therapy*; D003713:Dendritic Cells / Q000166:cytology; D018450:Disease Progression; D006801:Humans; D008495:Medical Oncology / Q000379:methods / Q000639:trends; D008954:Models, Biological; D009361:Neoplasm Invasiveness; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism
D019496:Cancer Vaccines; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human